Identification of microRNA and epigenome abnormality in colorectal cancer based on molecular subtype
| Project/Area Number |
16K07145
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor diagnostics
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | EZH2 / microRNA / 大腸癌 / microRNA-31 / IL-6 / バイオマーカー / ヒストン / エピゲノム / 分子標的治療 |
|---|
| Outline of Final Research Achievements |
MicroRNAs can function as oncogenes or tumour suppressors. Therefore, they have been increasingly recognized as useful biomarkers for various human cancers. With regard to colorectal cancers (CRCs), using miRNA array analysis, we recently discovered that microRNA-31 (miR-31) expression is significantly up-regulated in BRAF-mutated colorectal cancers (CRCs) compared with that in wild-type CRCs. Moreover, associations were identified between miR-31 expression, proximal tumor location and poor prognosis for CRCs. Moreover, the results of functional analysis showed that miR-31 may regulate BRAF activation and that the oncogenic role of miR-31 and its possibility of therapeutic target in CRCs. Thus, our current data suggest that miR-31 may be a diagnostic biomarker and therapeutic target in CRC. These novel data may lead to the establishment of a new therapeutic target or a theranostic procedure in gastroenterological cancers.
|
| Academic Significance and Societal Importance of the Research Achievements |
今回、我々は大腸癌においてEZH2がmiR-31の発現を制御することを世界で初めて明らかにした。癌の発育進展に関わるmicroRNAを制御するポリコームタンパク阻害剤やHDAC阻害剤、DNA 脱メチル化酵素などを同定することは新たな治療方法を開発できる可能性があるため、今後も本研究をさらに発展させたいと考えている。
|
Report
(4 results)
Research Products
(14 results)
-
-
-
[Journal Article] Impact of loss-of-function mutation at the RNF43 locus on colorectal cancer development and progression.2018
Author(s)
Eto T, Miyake K, Nosho K, Ohmuraya M, Imamura Y, Arima K, Kanno S, Fu L, Kiyozumi Y, Izumi D, Sugihara H, Hiyoshi Y, Miyamoto Y, Sawayama H, Iwatsuki M, Baba Y, Yoshida N, Furukawa T, Araki K, Baba H, Ishimoto T
-
Journal Title
J Pathol.
Volume: 245
Pages: 445-455
DOI
Related Report
Peer Reviewed
-
[Journal Article] Genetic Mechanisms of Immune Evasion in Colorectal Cancer2018
Author(s)
Grasso CS, Giannakis M, Wells DK, Hamada T, Mu XJ, Quist M, Nowak JA, Nishihara R, Qian ZR, Inamura K, Morikawa T, Nosho K, et al.
-
Journal Title
Cancer Discovery
Volume: 印刷中
Pages: 730-749
DOI
Related Report
Peer Reviewed / Int'l Joint Research
-
-
-
[Journal Article] The relationship between EZH2 expression and microRNA-31 in colorectal cancer and the role in evolution of the serrated pathway.2016
Author(s)
Kurihara H, Maruyama R, Ishiguro K, Kanno S, Yamamoto I, Ishigami K, Mitsuhashi K, Igarashi H, Ito M, Tanuma T, Sukawa Y, Okita K, Hasegawa T, Imai K, Yamamoto H, Shinomura Y, Nosho K.
-
Journal Title
Oncotarget
Volume: 7
Issue: 11
Pages: 12704-120717
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
-
-
-
-
